The stock jumped 12% to $3.05 in early trading, providing a much-needed boost for the imaging firm. Prior to this rally, Nanox shares had struggled significantly, declining approximately 62% over the past 52 weeks. This regulatory milestone marks a key step in the company’s effort to commercialize its proprietary digital X-ray technology and expand its footprint in the clinical diagnostics market.

Advanced Diagnostic Capabilities

The newly cleared TAP2D feature integrates directly with Nanox’s digital tomosynthesis systems, which are designed to create 3D-like reconstructions of internal anatomy. By utilizing this software, radiologists can now access a traditional 2D view alongside the 3D data from a single scan. According to the company, this dual-view capability helps clinicians better identify abnormalities while ensuring patients are not subjected to the additional radiation typically required for separate 2D and 3D procedures.

Nanox plans to deploy the enhancement software across its existing global installations as part of a broader rollout of imaging improvements. The company aims to position its technology as a more accessible and cost-effective alternative to traditional, high-voltage X-ray tubes, targeting medical facilities that require high-resolution imaging with a lower footprint. The FDA clearance specifically covers the software's ability to provide these enhanced views within the company's existing hardware ecosystem.